Data Insights

Brenetafusp by Immunocore for Ovarian Cancer: Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Ovarian Cancer

Data Insights

Brenetafusp by Immunocore for Melanoma: Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase III for Melanoma. According to GlobalData, Phase III drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Melanoma

Data Insights

Brenetafusp by Immunocore for Small-Cell Lung Cancer: Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Small-Cell Lung Cancer

Data Insights

Brenetafusp by Immunocore for Endometrial Cancer: Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Endometrial Cancer

Data Insights

Brenetafusp by Immunocore for Non-Small Cell Lung Cancer: Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Non-Small Cell Lung Cancer

Data Insights

Brenetafusp by Immunocore for Fallopian Tube Cancer: Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Fallopian Tube Cancer

Data Insights

Brenetafusp by Immunocore for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

Brenetafusp by Immunocore for Peritoneal Cancer: Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Peritoneal Cancer

Data Insights

Brenetafusp by Immunocore for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Brenetafusp by Immunocore for Synovial Sarcoma: Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Synovial Sarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Synovial Sarcoma

Data Insights

Brenetafusp by Immunocore for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Brenetafusp is under clinical development by Immunocore and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Brenetafusp in Triple-Negative Breast Cancer (TNBC)

Data Insights

Risk adjusted net present value: What is the current valuation of Immunocore's Brenetafusp?

Brenetafusp is a fusion protein commercialized by Immunocore, with a leading Phase III program in Melanoma. According to Globaldata, it...

Net Present Value Model: Immunocore Holdings Plc's Brenetafusp